STING and LTβR Activation Enhances Anti-Tumor Immunity in Mouse Models

Johns Hopkins All Children's Hospital researchers demonstrated that simultaneous activation of STING and LTβR proteins significantly inhibits tumor growth in mice. The study, published in *Nature Immunology*, investigated methods to convert immune-suppressed tumors into immune-responsive ones. Scientists targeted breast, pancreatic, and muscle cancer models, aiming to improve the efficacy of cancer treatments. By activating both STING and LTβR, researchers observed a rapid T-cell response and the formation of functional tertiary lymphoid structures (TLS). These structures are crucial for orchestrating anti-tumor immune responses. The induced TLS amplified the body's natural defenses against cancer, enabling immune cells to more effectively target malignant cells. Researchers found that this approach enhanced the effectiveness of both chemotherapy and immunotherapy. Masanobu Komatsu, a lead author, suggests the findings indicate broad applicability across various cancer treatment modalities. The study highlights a potential strategy for overcoming immune resistance in tumors and improving patient outcomes by leveraging the body's own immune system.